Englander Institute for Precision Medicine
Found 899 results
Author Title Type [ Year(Asc)]
Filters: Corrigendum-whole-genome-and-transcriptome-analysis-pancreatic-acinar-cell-carcinoma is   [Clear All Filters]
2024
Lukose G, Assaad MAl, Driskill JH, Levine MF, Gundem G, Semaan A, Wilkes DC, Spigland NA, Medina-Martínez JS, Sboner A et al..  2024.  Whole genome profiling of rare pediatric thoracic tumors elucidates a YAP1::LEUTX fusion in an unclassified biphasic embryonal neoplasm.. Pathol Res Pract. 264:155726.
Stephan C, Assaad MAl, Levine MF, Deshpande A, Sigouros M, Manohar J, Sboner A, Elemento O, Pavlick AC, Mosquera JMiguel.  2024.  Whole genome sequencing elucidates etiological differences in MCPyV-negative Merkel cell carcinoma.. Pathol Res Pract. 263:155668.
Assaad MAl, Michaud O, Semaan A, Sigouros M, Tranquille M, Phan A, Levine MF, Gundem G, Medina-Martínez JS, Papaemmanuil E et al..  2024.  Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets.. Mod Pathol. 37(4):100452.
2023
Weinstock JS, Gopakumar J, Burugula BBharathi, Uddin MMesbah, Jahn N, Belk JA, Bouzid H, Daniel B, Miao Z, Ly N et al..  2023.  Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.. Nature. 616(7958):755-763.
Kasi PMurtaza, Afable MGeroy, Herting C, Lukanowski M, Jin Z.  2023.  Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.. Oncologist. 28(12):1034-1048.
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L et al..  2023.  Apoptotic cell death in disease-Current understanding of the NCCD 2023.. Cell Death Differ. 30(5):1097-1154.
Mak L, Meleshko D, Danko DC, Barakzai WN, Maharjan S, Belchikov N, Hajirasouliha I.  2023.  Ariadne: synthetic long read deconvolution using assembly graphs.. Genome Biol. 24(1):197.
Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, Lin T-Y, Liberatore K, Cizin DM, Cohen BM et al..  2023.  An atlas of substrate specificities for the human serine/threonine kinome.. Nature. 613(7945):759-766.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S et al..  2023.  Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.. NPJ Precis Oncol. 7(1):113.
Hsiehchen D, Bucheit L, Yang D, Beg MShaalan, Lim M, Lee SS, Kasi PMurtaza, Kaseb AO, Zhu H.  2023.  Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.. Nat Commun. 14(1):7621.
Santambrogio L.  2023.  Autoimmunity to the modified self.. Science. 379(6637):1092-1093.
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
Grivas P, Grande E, Davis ID, Moon HH, Grimm M-O, Gupta S, Barthélémy P, Thibault C, Guenther S, Hanson S et al..  2023.  Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.. ESMO Open. 8(6):102050.
Hajirasouliha I, Semrau S.  2023.  Back in 3D-a report on Genome Informatics 2022.. Genome Biol. 24(1):57.
Boeck N, Trajanoski Z, Galluzzi L.  2023.  Bacterial antigens unleash tumor-targeting immunity.. Cell Host Microbe. 31(12):1945-1947.
Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre C-A, Lehmann CHK, Pan H, Paulhan N, Amon L et al..  2023.  BCL2 Inhibition Reveals a Dendritic Cell-Specific Immune Checkpoint That Controls Tumor Immunosurveillance.. Cancer Discov. 13(11):2448-2469.
Cultrara C, Uhl C, Kirby K, Elrazaq EAbed, Zellander A, Andrews DW, Scott CB, Galluzzi L, Exley MA, Zilberberg J.  2023.  A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.. J Immunother Cancer. 11(8)
Minoli M, Cantore T, Hanhart D, Kiener M, Fedrizzi T, La Manna F, Karkampouna S, Chouvardas P, Genitsch V, Rodriguez-Calero A et al..  2023.  Bladder cancer organoids as a functional system to model different disease stages and therapy response.. Nat Commun. 14(1):2214.
Choi S, Whitman MA, Shimpi AA, Sempertegui ND, Chiou AE, Druso JE, Verma A, Lux SC, Cheng Z, Paszek M et al..  2023.  Bone-matrix mineralization dampens integrin-mediated mechanosignalling and metastatic progression in breast cancer.. Nat Biomed Eng. 7(11):1455-1472.
Santambrogio L, Marrack P.  2023.  The broad spectrum of pathogenic autoreactivity.. Nat Rev Immunol. 23(2):69-70.
Dhaouadi N, Vitto VAngela Mar, Pinton P, Galluzzi L, Marchi S.  2023.  Ca signaling and cell death.. Cell Calcium. 113:102759.
Guilbaud E, Kroemer G, Galluzzi L.  2023.  Calreticulin exposure orchestrates innate immunosurveillance.. Cancer Cell. 41(6):1014-1016.
Galassi C, Galluzzi L.  2023.  Cancer stem cell immunoediting by IFNγ.. Cell Death Dis. 14(8):538.
Galluzzi L, Myint M.  2023.  Cell death and senescence.. J Transl Med. 21(1):425.